Skip to main
DXCM

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 52%
Buy 35%
Hold 9%
Sell 4%
Strong Sell 0%

Bulls say

DexCom is a strong investment opportunity due to its positive clinical data, potential for CGM adoption, and a well-developed product pipeline. Recent studies and results have shown the clinical effectiveness and potential market expansion of CGM use, leading to a Buy rating and lowered price target of $80 from analysts. The company's focus on expanding CGM adoption and strong financial performance, with expected revenue and EPS growth, make it a promising stock for investors seeking growth in the healthcare sector.

Bears say

DexCom is facing several key risks including potential pricing pressures, competition, and high levels of investment needed to compete effectively in the diabetes device sector. However, the company has shown strong margins, with adjusted gross margin and adjusted operating margin beating expectations and adjusted EBITDA margin outperforming TD Cowen's and consensus targets. Additionally, the company has a strong cash position and is actively pursuing Medicare coverage for its technology, which could provide a significant boost to its market success and potential market opportunity in the near future. Despite these positives, the lack of traditional and/or more mature financial metrics makes it difficult to assign a specific price target.

DexCom (DXCM) has been analyzed by 23 analysts, with a consensus rating of Buy. 52% of analysts recommend a Strong Buy, 35% recommend Buy, 9% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 23 analysts, DexCom (DXCM) has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $85.48, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $85.48, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.